Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

The Clostridioides Difficile Trial of REC-3964

← catalyst calendar

NCT06536465 · results posted

Sponsored by Recursion Pharmaceuticals Inc. (industry) · RXRX — their whole pipeline →.

Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
3actual
Sites
2
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Study was terminated due to sponsor decision. This decision was not related to safety concerns.

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-10-14actualWhen the study began enrolling
Primary completion2025-05-06actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-05-06actualThe whole study's end, after follow-up
First posted2024-08-05actualWhen this record first appeared on the registry
Results posted2025-11-17actualWhen the sponsor posted results to the registry
Record updated2025-11-17actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Recurrent Clostridioides Difficile Infection

Intervention

  • Drug: REC-3964

Primary outcomes

what the primary-completion date above is the date OF
Number of Participants With Survival Without Recurrence or Requirement for Additional Clostridioides Difficile Infection (CDI) Treatment
measured 8 weeks
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
measured Up to 8 weeks
Number of Participants With Related TEAEs
measured Up to 8 weeks
Number of Participants With Serious TEAEs
measured Up to 8 weeks
Number of Participants With TEAEs Leading to Study Drug Discontinuation
measured Up to 8 weeks

Posted documents

hosted by the registry — we link, never re-serve
Study Protocol and Statistical Analysis Planposted 2025-03-27 · 691 KB · Prot_SAP_000.pdf

Permalink · RXRX's whole pipeline · Catalyst calendar · Every registered study · What changed